FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID AFFR	OVAL				
OMB Number:	3235-0287				
Estimated average bur	den				
hours per response:	0.5				

OME ADDDOMAI

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Graf R. Mark					2. Issuer Name and Ticker or Trading Symbol Harmony Biosciences Holdings, Inc. [HRMY]								heck all ap	plicable) ctor	Ü	rson(s) to Iss	vner	
(Last)	,	irst) ((Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/29/2024								bel	er (give title v)		Other (s below)	specify	
INC. 630 W GERMANTOWN PIKE, SUITE 215					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)														n filed by Moson	ore tha	n One Repo	rting	
PLYMOU MEETIN	- P,	A	19462		Rule 10b5-1(c) Transaction Indication													
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									d to				
		Tab	le I - Non-I	Derivat	ive S	ecuritie	s Ac	quired, C	isp	osed c	f, or Be	neficia	lly Owr	ed				
Date				:. Transact Date Month/Day	Execution Date			r, Transaction Dispose Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) o (D)	r Price	Trans	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	nsactio de (Instr		tive ties red sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price Derivati Security (Instr. 5)		e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ie V	(A)	(D)	Date Exercisable	Ex _I Da	piration te	Title	Amount or Number of Shares						
Stock Option	\$29.33	05/29/2024		A		6,336		(1)	05/	/29/2034	Common Stock	6,336	\$0	6,33	6	D		

Explanation of Responses:

1. The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

/s/ Christian Ulrich, Attorneyin-Fact

05/31/2024

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.